title: Antibiotic prophylaxis in cardiac surgery: serum and tissue levels of teicoplanin, flucloxacillin and tobramycin.
abstract: In this study, the pharmacokinetics of teicoplanin have been studied in serum, fat and bone during and after cardiac surgery with two dose (400 and 200 mg) and three dose (400 mg each) regimens in a total of 49 patients. For comparison, 20 other patients, who had received a regimen of flucloxacillin (500 mg qds for five days) and tobramycin (1.5 mg/kg initially then 80 mg tds for three days), were similarly investigated. The lowest mean serum level of teicoplanin during operation was 6.9 mg/l in the two dose regimen and 9.7 mg/l with the three dose regimen. Mean serum levels of flucloxacillin and tobramycin fell to 7 and 1.4 mg/l respectively by the end of operation. At the end of bypass, fat washings contained a mean of 1.2 mg/l of teicoplanin and bone washings a mean of 6.3 mg/l. Mean tobramycin levels were 0.4 and 0.9 mg/l respectively and flucloxacillin less than 1 mg/l in washings from both tissues. The low levels of teicoplanin in fat may explain an excess of Gram-positive sternal infections in the accompanying clinical trial.
authors.affiliation: Department of Microbiology, University College Hospital, London, UK.
authors.forename: A P
authors.initials: AP
authors.lastname: Wilson
authors.forename: B
authors.initials: B
authors.lastname: Taylor
authors.forename: T
authors.initials: T
authors.lastname: Treasure
authors.forename: R N
authors.initials: RN
authors.lastname: Grüneberg
authors.forename: K
authors.initials: K
authors.lastname: Patton
authors.forename: D
authors.initials: D
authors.lastname: Felmingham
authors.forename: M F
authors.initials: MF
authors.lastname: Sturridge
mesh_terms: D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000517:prevention & control*; D006348:Cardiac Surgical Procedures / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D005436:Floxacillin / Q000493:pharmacokinetics / Q000627:therapeutic use; D006020:Glycopeptides / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D013530:Surgical Wound Infection / Q000517:prevention & control*; D017334:Teicoplanin; D014018:Tissue Distribution; D014031:Tobramycin / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D005436:Floxacillin; D017334:Teicoplanin; D014031:Tobramycin